Philip Lipari

525 total citations
6 papers, 337 citations indexed

About

Philip Lipari is a scholar working on Molecular Biology, Oncology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Philip Lipari has authored 6 papers receiving a total of 337 indexed citations (citations by other indexed papers that have themselves been cited), including 2 papers in Molecular Biology, 2 papers in Oncology and 2 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Philip Lipari's work include Cancer-related Molecular Pathways (2 papers), Cancer Research and Treatments (2 papers) and Growth Hormone and Insulin-like Growth Factors (2 papers). Philip Lipari is often cited by papers focused on Cancer-related Molecular Pathways (2 papers), Cancer Research and Treatments (2 papers) and Growth Hormone and Insulin-like Growth Factors (2 papers). Philip Lipari collaborates with scholars based in United States. Philip Lipari's co-authors include Maya Gurnani, Janet Dell, Bin Shi, Loretta L. Nielsen, Yaolin Wang, W. Robert Bishop, Robert Ramos, Jonathan A. Pachter, Yan Wang and Susan Cannon‐Carlson and has published in prestigious journals such as Cancer Research, Analytical Biochemistry and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Philip Lipari

6 papers receiving 319 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Philip Lipari United States	5	223	118	98	71	54	6	337
Donna Hewitt Canada	5	194 0.9×	94 0.8×	25 0.3×	63 0.9×	43 0.8×	12	351
Beverly S. Adler United States	7	321 1.4×	57 0.5×	54 0.6×	72 1.0×	46 0.9×	9	469
Andrew R. Zaretsky Russia	10	237 1.1×	118 1.0×	40 0.4×	169 2.4×	32 0.6×	28	431
F G Hay United Kingdom	5	200 0.9×	166 1.4×	15 0.2×	54 0.8×	43 0.8×	9	375
Jinrong Cheng United States	7	261 1.2×	78 0.7×	18 0.2×	68 1.0×	18 0.3×	14	350
Ignazia La Torre Italy	11	150 0.7×	136 1.2×	15 0.2×	51 0.7×	68 1.3×	30	335
Philip K. Hall United States	8	252 1.1×	50 0.4×	27 0.3×	77 1.1×	30 0.6×	12	454
Paul Hachem United States	12	135 0.6×	111 0.9×	14 0.1×	55 0.8×	31 0.6×	20	331
A. Seun Ajiboye United States	4	170 0.8×	85 0.7×	92 0.9×	65 0.9×	42 0.8×	6	359
Yunlim Kim South Korea	12	193 0.9×	59 0.5×	11 0.1×	93 1.3×	29 0.5×	24	334

Countries citing papers authored by Philip Lipari

Since Specialization

Citations

This map shows the geographic impact of Philip Lipari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip Lipari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip Lipari more than expected).

Fields of papers citing papers by Philip Lipari

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip Lipari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip Lipari. The network helps show where Philip Lipari may publish in the future.

Co-authorship network of co-authors of Philip Lipari

This figure shows the co-authorship network connecting the top 25 collaborators of Philip Lipari. A scholar is included among the top collaborators of Philip Lipari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip Lipari. Philip Lipari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Miesel, Lynn, David W. Hecht, James R. Osmolski, et al.. (2014). Kibdelomycin Is a Potent and Selective Agent against Toxigenic Clostridium difficile. Antimicrobial Agents and Chemotherapy. 58(4). 2387–2392. 21 indexed citations

2.

Wang, Yaolin, Philip Lipari, Xiaoying Wang, et al.. (2010). A Fully Human Insulin-Like Growth Factor-I Receptor Antibody SCH 717454 (Robatumumab) Has Antitumor Activity as a Single Agent and in Combination with Cytotoxics in Pediatric Tumor Xenografts. Molecular Cancer Therapeutics. 9(2). 410–418. 39 indexed citations

3.

Wang, Yaolin, Xiaoying Wang, Philip Lipari, et al.. (2008). SCH 727965, a novel cyclin-dependent kinase inhibitor, has potent anti-tumor acitivity in a wide-spectrum of human tumor xenograft models. Cancer Research. 68. 1594–1594. 1 indexed citations

4.

Wang, Yan, Denise Williams, Yaolin Wang, et al.. (2005). Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti–IGF-IR antibody. Molecular Cancer Therapeutics. 4(8). 1214–1221. 140 indexed citations

5.

Zhang, Rumin, Todd Mayhood, Philip Lipari, et al.. (2004). Fluorescence polarization assay and inhibitor design for MDM2/p53 interaction. Analytical Biochemistry. 331(1). 138–146. 43 indexed citations

6.

Gurnani, Maya, Philip Lipari, Janet Dell, Bin Shi, & Loretta L. Nielsen. (1999). Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer. Cancer Chemotherapy and Pharmacology. 44(2). 143–151. 93 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact